Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Taysha Gene Therapies has reported Current Deferred Revenue for 4 years, with the latest figure at $5.5 million in Q3 2025.

• Quarterly Current Deferred Revenue fell 53.37% year-over-year to $5.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.5 million (down 53.37% YoY) and the FY2024 annual result came in at $9.8 million, down 46.02% from the prior year.
• Current Deferred Revenue held at $5.5 million in Q3 2025 per TSHA's latest filing, from $5.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $33.6 million in Q4 2022 and troughed at $5.5 million in Q2 2025.
• A 4-year average of $15.7 million and a median of $14.1 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue sank 32.9% in 2024, then plunged 59.51% in 2025.
• Over 4 years, Current Deferred Revenue stood at $33.6 million in 2022, then slumped by 46.04% to $18.1 million in 2023, then slumped by 46.02% to $9.8 million in 2024, then tumbled by 43.72% to $5.5 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $5.5 million, $5.5 million, and $7.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.